FDA Grants Fast Track Designation to CTIM-76 for Platinum-Resistant Ovarian Cancer - Targeted Oncology
FDA Grants Fast Track Designation to CTIM-76 for Platinum-Resistant Ovarian Cancer Targeted Oncology
Ovarian Cancer News
Relacorilant Plus Nab-Paclitaxel Approved for Platinum-Resistant Ovarian Cancer - Clinical Oncology News
Relacorilant Plus Nab-Paclitaxel Approved for Platinum-Resistant Ovarian Cancer Clinical Oncology News
Relacorilant/Nab-Paclitaxel Offers New Option in Platinum-Resistant Ovarian Cancer - CancerNetwork
Relacorilant/Nab-Paclitaxel Offers New Option in Platinum-Resistant Ovarian Cancer CancerNetwork
Gynecologic Oncologists Preview the Abstracts Set to Drive Conversation at SGO 2026 - OncLive
Gynecologic Oncologists Preview the Abstracts Set to Drive Conversation at SGO 2026 OncLive
MSD secures EC clearance for Keytruda combination therapy for ovarian cancer - Pharmaceutical Technology
MSD secures EC clearance for Keytruda combination therapy for ovarian cancer Pharmaceutical Technology
Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis - BioSpace
Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis BioSpace
Gilead to Acquire Tubulis for Up to $5B, Expanding Cancer ADC Capabilities - Genetic Engineering and Biotechnology News
Gilead to Acquire Tubulis for Up to $5B, Expanding Cancer ADC Capabilities Genetic Engineering and Biotechnology News
Gilead to Buy German Biotech Tubulis for Up to $5 Billion. The Stock Falls. - Barron's
Gilead to Buy German Biotech Tubulis for Up to $5 Billion. The Stock Falls. Barron's
Wiltshire woman urges awareness of ovarian cancer signs - BBC
Wiltshire woman urges awareness of ovarian cancer signs BBC
NextCure Gets FDA Fast Track for SIM0505 in Ovarian Cancer - National Today
NextCure Gets FDA Fast Track for SIM0505 in Ovarian Cancer National Today
Gilead to Buy Cancer Biotech Tubulis in $5 Billion Deal - Bloomberg.com
Gilead to Buy Cancer Biotech Tubulis in $5 Billion Deal Bloomberg.com
Ernexa Therapeutics Advances Toward 2026 Human Trials - The Clinical Trial Vanguard
Ernexa Therapeutics Advances Toward 2026 Human Trials The Clinical Trial Vanguard
Gilead buying Tubulis and its ADCs in $5B takeover bid - BioWorld MedTech
Gilead buying Tubulis and its ADCs in $5B takeover bid BioWorld MedTech
Gilead’s Pipeline Strategy Takes Shape With $3B Acquisition of Cancer Biotech Tubulis - MedCity News
Gilead’s Pipeline Strategy Takes Shape With $3B Acquisition of Cancer Biotech Tubulis MedCity News
Health in NI: Do 40% of women wrongly believe cervical smear tests for ovarian cancer? - FactCheckNI
Health in NI: Do 40% of women wrongly believe cervical smear tests for ovarian cancer? FactCheckNI
Early Menarche and Late Menopause Key Determinants of Ovarian Cancer Risk: JAMA - Medical Dialogues
Early Menarche and Late Menopause Key Determinants of Ovarian Cancer Risk: JAMA Medical Dialogues
FDA Grants Fast Track Designation to CTIM-76 for Platinum-Resistant Ovarian Cancer - OncLive
FDA Grants Fast Track Designation to CTIM-76 for Platinum-Resistant Ovarian Cancer OncLive
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026 - BioSpace
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026 BioSpace
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline - BioSpace
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline BioSpace
FDA Approves Relacorilant Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer - OncLive
FDA Approves Relacorilant Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer OncLive
'How I knew I had ovarian cancer’: Survivors and caregiver discuss symptoms - UT MD Anderson
'How I knew I had ovarian cancer’: Survivors and caregiver discuss symptoms UT MD Anderson
FGFR1 Halts Ovarian Cancer via Metabolic Shift - Bioengineer.org
FGFR1 Halts Ovarian Cancer via Metabolic Shift Bioengineer.org
Three-pronged treatment could be more effective against ovarian cancer, local study says - San Diego Union-Tribune
Three-pronged treatment could be more effective against ovarian cancer, local study says San Diego Union-Tribune
Olympic Ice Dancer Piper Gilles Survived Ovarian Cancer. Here’s What to Know About the Disease. - University of Colorado Anschutz
Olympic Ice Dancer Piper Gilles Survived Ovarian Cancer. Here’s What to Know About the Disease. University of Colorado Anschutz
What Was 2025’s Biggest News in Ovarian Cancer? - Oncology News Central
What Was 2025’s Biggest News in Ovarian Cancer? Oncology News Central
Audra Moran | Notable Leaders in Health Care 2026 - Crain's New York
Audra Moran | Notable Leaders in Health Care 2026 Crain's New York
Anixa Biosciences to Present at Water Tower Research Insights Conference - National Today
Anixa Biosciences to Present at Water Tower Research Insights Conference National Today
Cannabis derivatives could provide new ovarian cancer treatments - Frontiers
Cannabis derivatives could provide new ovarian cancer treatments Frontiers
Rewiring Immune System Offers New Path to Better Ovarian Cancer Treatment - UC San Diego Today
Rewiring Immune System Offers New Path to Better Ovarian Cancer Treatment UC San Diego Today
Targeted Therapy Boosts Immune Attack in Ovarian Cancer - Bioengineer.org
Targeted Therapy Boosts Immune Attack in Ovarian Cancer Bioengineer.org
Lung cancer drug offers a surprising new treatment against ovarian cancer - Mayo Clinic News Network
Lung cancer drug offers a surprising new treatment against ovarian cancer Mayo Clinic News Network
EU Ovarian Cancer Nod and New Trials Might Change The Case For Investing In Merck (MRK) - simplywall.st
EU Ovarian Cancer Nod and New Trials Might Change The Case For Investing In Merck (MRK) simplywall.st
Binghamton researchers target ovarian and pancreatic cancer - Binghamton University
Binghamton researchers target ovarian and pancreatic cancer Binghamton University
More Than a Notch: New Discovery May Improve Ovarian Cancer Treatment - UNM HSC Newsroom
More Than a Notch: New Discovery May Improve Ovarian Cancer Treatment UNM HSC Newsroom
Genomic alterations linked to recurrence risk in high-grade serous ovarian cancer revealed by deep targeted sequencing - Nature
Genomic alterations linked to recurrence risk in high-grade serous ovarian cancer revealed by deep targeted sequencing Nature
FDA Approves New Combination Therapy for Platinum-Resistant Ovarian Cancer – OCRF - Oncodaily
FDA Approves New Combination Therapy for Platinum-Resistant Ovarian Cancer – OCRF Oncodaily
One Surgery Could Prevent Most Ovarian Cancers - The American College of Surgeons
One Surgery Could Prevent Most Ovarian Cancers The American College of Surgeons
“We Need More Advocacy”: Tackling the Biggest Challenges in Ovarian Cancer Care - Oncology News Central
“We Need More Advocacy”: Tackling the Biggest Challenges in Ovarian Cancer Care Oncology News Central
Gilead Sciences Acquires Tubulis for $3 Billion - National Today
Gilead Sciences Acquires Tubulis for $3 Billion National Today
UCLA scientists develop off-the-shelf immunotherapy for ovarian cancer - Newsroom | UCLA
UCLA scientists develop off-the-shelf immunotherapy for ovarian cancer Newsroom | UCLA